Study guide

8.2 Mydriatics, Cycloplegics & Diagnostic Ophthalmic Dyes

IJCAHPO Certified Retina Technician CRT

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview: Current CRT Requirements & Blueprint

Exam Overview: Current Requirements, Scope & Study Plan

2 Chapter 1: History Taking, Triage & Clinical Documentation

1.1 Comprehensive Ophthalmic & Medical History for Retina Patients 1.2 Telephone Triage, Urgent Symptoms & Emergency Scheduling 1.3 Scribing, Electronic Health Records & Retinal Billing Codes

3 Chapter 2: Visual Assessment & Low Vision Rehabilitation

2.1 Standardized Visual Acuity Testing & Optotypes 2.2 Sub-Chart Acuity Protocols: CF, HM, LP, and NLP 2.3 Low Vision Definitions, Optical Devices & Patient Counseling

4 Chapter 3: Pupil Assessment & Visual Field Testing

3.1 Pupillary Examination & Relative Afferent Pupillary Defect 3.2 Confrontation Fields & Automated Perimetry in Retina 3.3 Amsler Grid Testing & Metamorphopsia Monitoring

5 Chapter 4: Tonometry & Ocular Motility

4.1 Goldmann Applanation & Handheld Tonometry Techniques 4.2 Tonometer Disinfection, Calibration & Post-Procedure IOP Monitoring 4.3 Ocular Motility Assessment, Strabismus & Alignment Testing

6 Chapter 5: Diagnostic Ophthalmic Ultrasound

5.1 Ophthalmic B-Scan Echography for Posterior Segment Pathology 5.2 Standardized A-Scan Echography & Optical Biometry

7 Chapter 6: Slit Lamp, Electrophysiology & Supplemental Testing

6.1 Slit Lamp Biomicroscopy, Illumination & Fundus Lenses 6.2 Color Vision Assessment & Hertel Exophthalmometry 6.3 Ophthalmic Electrophysiology: ERG, VEP, and EOG

8 Chapter 7: Ophthalmic Microbiology & Infection Control

7.1 Ocular Pathogens & Routes of Disease Transmission 7.2 Clinical Asepsis, Universal Precautions & Vitreous Specimen Collection

9 Chapter 8: General Retinal Pharmacology & Therapeutics

8.1 Ocular Drug Delivery Methods & Routes of Administration 8.2 Mydriatics, Cycloplegics & Diagnostic Ophthalmic Dyes 8.3 Anesthetics, Glaucoma Agents & Prescription Verification

10 Chapter 9: Anti-VEGF Therapies, Steroids & Retinal Toxicity

9.1 Anti-VEGF Agents & Neovascular Retinal Diseases 9.2 Corticosteroids, Sustained-Release Implants & AREDS Supplements 9.3 Systemic Medication Retinal Toxicity & Plaquenil Screening

11 Chapter 10: Surgical Assisting & Intravitreal Procedures

10.1 Intravitreal Injection Protocol, Antisepsis & Complication Checks 10.2 Retinal Laser Therapy Modalities & Laser Safety Protocols 10.3 Surgical Instrument Handling, Tray Setup & Sterilization

12 Chapter 11: Patient Services, Education & Clinical Care

11.1 Patient Education, Chronic Disease Counseling & Treatment Adherence 11.2 Special Needs Accommodations, Patient Diversity & Interpersonal Skills 11.3 Ophthalmic Emergencies, First Aid & Clinical Care Coordination 11.4 Clinic Operations, Research Support, Forms & Referrals

13 Chapter 12: General Ocular Anatomy & Retinal Physiology

12.1 Ocular Anatomy, Orbit & Posterior Segment Architecture 12.2 Ten Retinal Layers, Photoreceptors & Macular Anatomy 12.3 Ocular Blood Supply, Microcirculation & Vitreoretinal Interface 12.4 Body Systems, Ocular Adnexa & Medical Terminology

14 Chapter 13: Retinal Pathology & Systemic Disease Manifestations

13.1 Age-Related Macular Degeneration & Retinal Vascular Occlusions 13.2 Diabetic Retinopathy & Systemic Diseases Affecting the Retina 13.3 Peripheral Retinal Degenerations, Tears & Detachments

15 Chapter 14: Ophthalmic Optics & Lensometry

14.1 Principles of Ophthalmic Optics & Refraction 14.2 Manual & Automated Lensometry Techniques

16 Chapter 15: Fundus Photography & Ophthalmic Angiography

15.1 Fundus Photography Techniques & Fundus Autofluorescence 15.2 Fluorescein Angiography Principles, Phases & Image Interpretation 15.3 Indocyanine Green Angiography & Angiographic Complication Management

17 Chapter 16: Optical Coherence Tomography (OCT & OCT-A)

16.1 OCT Principles, Scan Acquisition & Artifact Recognition 16.2 Structural OCT Interpretation: Retinal Fluid & Biomarkers 16.3 Optical Coherence Tomography Angiography (OCT-A) Principles & Flow

18 Chapter 17: Equipment Maintenance, Ethics & Regulatory Compliance

17.1 Equipment Maintenance, Calibration Schedules & Clinic Safety 17.2 Medical Ethics, Scope of Practice & Informed Consent 17.3 Patient Privacy, HIPAA Standards & Hazardous Waste Disposal

8.2 Mydriatics, Cycloplegics & Diagnostic Ophthalmic Dyes

Key Takeaways Explain This Topic AI

Tropicamide blocks muscarinic receptors to produce mydriasis with some cycloplegia; phenylephrine stimulates alpha-1 receptors and dilates without cycloplegia.

Drug selection and concentration depend on the patient, ordered examination, cardiovascular and neurologic history, angle assessment, age, and local protocol.

Fluorescein angiography and ICG angiography use different optical wavelengths and pharmacology; neither dye history should be reduced to the shellfish-allergy myth.

The current U.S. IC-GREEN label notes sodium iodide and calls for caution with iodide-allergy history, while reactions can occur with or without that history.

Verify patient, eye, agent, concentration, expiration, route, allergies, emergency readiness, and documentation before administration.

Last updated: September 2026

Mydriatics, Cycloplegics, and Diagnostic Dyes

Retina examinations often require dilation and sometimes angiographic contrast. These products are medications, not routine supplies. A technician works from an order or approved protocol and considers the patient's history, current drugs, anatomy, and prior reactions before instillation or injection.

Mydriasis and cycloplegia

Tropicamide is an antimuscarinic drug commonly used for diagnostic dilation. It relaxes the iris sphincter and ciliary muscle, so it produces mydriasis and some cycloplegia. Onset and duration vary with concentration, pigmentation, age, and other drugs.

Phenylephrine is an alpha-1 agonist that contracts the iris dilator. It does not provide cycloplegia. Systemic absorption can affect blood pressure and heart rhythm, especially with higher concentrations or susceptible patients. Verify cardiovascular history, interacting drugs, and the ordered concentration; use punctal occlusion or eyelid closure when protocol calls for it to reduce systemic absorption.

Longer-acting cycloplegics such as cyclopentolate, homatropine, or atropine have different indications and durations. No single drop is the universal best choice for every retina visit. The prescriber or standing protocol determines selection.

Angle and neurologic safety

A shallow peripheral chamber on screening is a reason to pause and notify the clinician, not an independent diagnosis of angle closure. The clinician considers gonioscopy, prior iridotomy, symptoms, and the need for dilation. After drops, urgent symptoms such as severe pain, headache, halos, nausea, a fixed mid-dilated pupil, or sudden vision reduction require immediate escalation.

Document baseline pupils before dilation when a neurologic or afferent examination is needed. Record agent, concentration, eye, time, and response.

Sodium fluorescein

Topical fluorescein supports corneal staining and applanation. Intravenous sodium fluorescein is used for retinal angiography. Verify the correct route and formulation: a topical strip or drop is not an injectable product. IV fluorescein can cause nausea, vomiting, urticaria, extravasation, and rarely a severe systemic reaction. Check prior reaction details and emergency readiness. The clinician decides whether premedication, an alternative test, or cancellation is appropriate.

Indocyanine green

ICG absorbs and emits near-infrared light and is highly protein-bound, which supports choroidal imaging through pigment and some hemorrhage. Current U.S. IC-GREEN labeling says the product contains no more than five percent sodium iodide and should be used with caution in a patient with a history of allergy to iodides because of anaphylaxis risk. It also states that reactions may occur with or without such a history.

Shellfish allergy is directed at seafood proteins and is not, by itself, an iodine allergy or automatic contraindication to ICG. Ask what product caused the reaction, the route, symptoms, severity, timing, and treatment. A prior ICG reaction or relevant iodide history goes to the clinician for risk assessment. Pregnancy, hepatic disease, or other comorbidity likewise requires clinician review rather than a memorized universal exclusion.

Safe administration workflow

Before any ordered dye or drop:

  • use two patient identifiers and confirm the eye and study;
  • verify product, route, concentration, dose, lot, expiration, and container integrity;
  • reconcile allergies and prior reactions using specific descriptions;
  • confirm IV patency for injectable dye and check emergency equipment;
  • explain expected sensations and warning symptoms without promising that a reaction cannot occur;

document administration and any event.

For extravasation, stop injection and follow the product and facility protocol. For airway symptoms, hypotension, rapidly progressive swelling, or multisystem reaction, stop the study and activate the emergency response. Medication treatment follows the authorized emergency protocol.

The central exam distinction is mechanism plus safety: antimuscarinic versus adrenergic dilation, topical versus intravenous fluorescein, and visible-light fluorescein versus near-infrared ICG.

Medication checks and adverse-response workflow

Before instillation, compare the authorized order with the patient, eye, drug, concentration, route, expiration, allergies or prior reactions, and relevant precautions. Inspect the bottle and tip, perform hand hygiene, avoid touching the ocular surface, and document the agent and time. Do not reuse a single-patient container across patients or override a warning because the same drops were tolerated previously.

After drops, monitor according to the drug, patient risk, and clinic protocol. New chest pain, severe headache, dyspnea, marked blood-pressure change, confusion, or allergic symptoms require immediate escalation. Ocular pain, nausea, halos, or a red eye after dilation can signal an acute pressure problem and also needs urgent review. A technician may recognize a concerning pattern but does not diagnose angle closure or independently select a reversal drug. When the pupil dilates poorly, verify timing and technique and notify the clinician rather than repeatedly dosing outside the order.